ArticleScientific reports2016
TNFR2 expression by CD4 effector T cells is required to induce full-fledged experimental colitis.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 50 citations in OpenAlex.
- A novel TNFR2 agonist peptide for the expansion of CD4+Foxp3+ regulatory T cells.Frontiers in immunology · 2025Article
- Identification of immune-related biomarkers associated with allergic rhinitis and development of a sample diagnostic model.PloS one · 2025Article
- The immune landscape of the inflamed joint defined by spectral flow cytometry.Clinical and experimental immunology · 2024Article
- TNFR1 signaling promotes pancreatic tumor growth by limiting dendritic cell number and function.Cell reports. Medicine · 2024Article
- Targeting cytokine and chemokine signaling pathways for cancer therapy.Signal transduction and targeted therapy · 2024Review
- Natural Products: A Dependable Source of Therapeutic Alternatives for Inflammatory Bowel Disease through Regulation of Tight Junctions.Molecules (Basel, Switzerland) · 2023Review
- TNFR2 antagonistic antibody induces the death of tumor infiltrating CD4Cellular oncology (Dordrecht, Netherlands) · 2023Article
- Therapeutic potential of TNFR2 agonists: a mechanistic perspective.Frontiers in immunology · 2023Review
- Article
- TNFR1 Contributes to Activation-Induced Cell Death of Pathological CD4JACC. Basic to translational science · 2022Article
- Alpha synuclein, the culprit in Parkinson disease, is required for normal immune function.Cell reports · 2022Article
- Computational Analysis Reveals the Characteristics of Immune Cells in Glomerular and Tubulointerstitial Compartments in IgA Nephropathy Patients.Frontiers in genetics · 2022Article
- The dichotomous outcomes of TNFα signaling in CD4Frontiers in immunology · 2022Review
- TNFR2 Costimulation Differentially Impacts Regulatory and Conventional CD4Frontiers in immunology · 2022Review
- TNF plays a crucial role in inflammation by signaling via T cell TNFR2.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Insights into the biology and therapeutic implications of TNF and regulatory T cells.Nature reviews. Rheumatology · 2021Review
- TNF in the era of immune checkpoint inhibitors: friend or foe?Nature reviews. Rheumatology · 2021Review
- TNF-TNFR2 Signal Plays a Decisive Role in the Activation of CD4Advances in experimental medicine and biology · 2021Article
- Brucella abortus and Pregnancy in Mice: Impact of Chronic Infection on Fertility and the Role of Regulatory T Cells in Tissue Colonization.Infection and immunity · 2020Article
- Selective Targeting of TNF Receptors as a Novel Therapeutic Approach.Frontiers in cell and developmental biology · 2020Review
Corrections and comments
- Erratum issued
Authors and funding
9 authors at 4 institutions in 3 countries.
Funding
Abstract
There is now compelling evidence that TNFR2 is constitutively expressed on CD4(+) Foxp3(+) regulatory T cells (Tregs) and TNF-TNFR2 interaction is critical for the activation, expansion and functional stability of Tregs. However, we showed that the expression of TNFR2 was also up-regulated on CD4(+) Foxp3(-) effector T cells (Teffs) upon TCR stimulation. In order to define the role of TNFR2 in the pathogenic CD4 T cells, we compared the effect of transferred naïve CD4 cells from WT mice and TNFR2(-/-) mice into Rag 1(-/-) recipients. Transfer of TNFR2-deficient Teff cells failed to induce full-fledged colitis, unlike WT Teffs. This was due to defective proliferative expansion of TNFR2-deficient Teff cells in the lymphopenic mice, as well as their reduced capacity to express proinflammatory Th1 cytokine on a per cell basis. In vitro, the proliferative response of TNFR2 deficient naïve CD4 cells to anti-CD3 stimulation was markedly decreased as compared with that of WT naïve CD4 cells. The hypoproliferative response of TNFR2-deficient Teff cells to TCR stimulation was associated with an increased ratio of p100/p52, providing a mechanistic basis for our findings. Therefore, this study clearly indicates that TNFR2 is important for the proliferative expansion of pathogenic Teff cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.